CLE Adverse Event Reporting 3

Question 1

A breastfeeding mother reports a rash after using a lanolin-based nipple cream. The CLE suspects an allergic contact dermatitis. Which body oversees adverse event reports for this type of topical product?

Accepted Answer

FDA Center for Drug Evaluation and Research (CDER) or CFSAN depending on product classification

Answer

Nipple creams may be regulated as OTC drugs (CDER) or cosmetics (CFSAN) depending on their claims, so the appropriate FDA center depends on product classification.

Question 2

Which statement about voluntary versus mandatory adverse event reporting is CORRECT in the US context?

Accepted Answer

Manufacturers must report serious device-related events; healthcare providers may report voluntarily

Answer

Under FDA regulations, device manufacturers and importers have mandatory reporting obligations, while healthcare professionals and consumers report voluntarily through MedWatch.

Question 3

After a breastfeeding infant is diagnosed with methemoglobinemia potentially linked to a nipple cleaning solution, the CLE should prioritize which action?

Accepted Answer

Preserve the product sample and lot number, then file a MedWatch report

Answer

Preserving product evidence and reporting to FDA MedWatch are critical steps when a product is suspected of causing a serious infant adverse event.

Question 4

A CLE working in a hospital notices a cluster of three infants with feeding difficulties all using the same silicone bottle nipple brand. What is the MOST appropriate escalation?

Accepted Answer

Report the cluster to the FDA as a potential signal, referencing all three cases

Answer

A cluster of similar adverse events with the same device constitutes a signal that should be formally reported to the FDA to trigger investigation.

Question 5

Which international framework guides pharmacovigilance standards that may influence how a US-based CLE understands global adverse event reporting?

Accepted Answer

WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre)

Answer

The WHO Uppsala Monitoring Centre coordinates international pharmacovigilance, establishing global standards that inform drug safety monitoring worldwide.

(CLE) Certified Lactation Educator Practice Test

(CLE) Certified Lactation Educator Practice Test

CLE Adverse Event Reporting 3